Jeffrey Burns, MD
Neurology · Kansas City, KSNPI 1780781377
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $103,256 of the $115,467 with a category attached, or 89.4%. 9 manufacturers reported payments, led by Lilly USA, LLC at 45.5% of the total. 2025 is the largest year on record at $48,852, more than ten times the $2,587 reported in 2019. Among neurology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $1297.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$53K
- Eisai Inc.$23K
- Novo Nordisk$10K
- AbbVie$9K
- Eli Lilly$8K
- Biogen$4K
- plus $8K from 3 others
Across 169 payments — averaging $36,299 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2.2M
- Biogen$1.4M
- AstraZeneca$946K
- AbbVie$786K
- Novartis$644K
- Janssen Research & Development, LLC$56K
- plus $151K from 6 others
What the payments were for
- Consulting fees$103,25689%
- Travel & lodging$9,9689%
- Food & beverage$2,2432%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 37 | $52,577 |
| Eisai Inc. | 15 | $23,272 |
| Novo Nordisk | 8 | $10,373 |
| AbbVie | 11 | $9,004 |
| Eli Lilly | 10 | $8,033 |
| Biogen | 5 | $3,744 |
| Roche Diagnostics Corporation | 1 | $3,348 |
| Avanir Pharmaceuticals, Inc. | 1 | $2,616 |
| Sage Therapeutics, LLC | 1 | $2,500 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$115,467 in reported general payments places this provider in the 95th percentile of 131 neurology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 46 | $7,178 |
| Donepezil Hcl | 516 | $5,542 |
| Galantamine ErGalantamine Hbr | 50 | $4,163 |
| Memantine Hcl | 137 | $3,207 |
| Escitalopram Oxalate | 124 | $1,369 |
| Quetiapine Fumarate | 43 | $688 |
| Sertraline Hcl | 47 | $277 |
| Trazodone Hcl | 26 | $150 |
Paid to pharmacies, not to this prescriber.
Other neurology in Kansas City
- Ivan OsorioKansas City$101.7M
- Rajesh PahwaKansas City$889K
- Richard DubinskyKansas City$122K
- Amanda ThuringerKansas City$87K
- Mamatha PasnoorKansas City$86K
- Michael AbrahamKansas City$48K
- Constantine FarmakidisKansas City$25K
- Andrew CreedKansas City$16K
- James AppelbaumKansas City$15K
- Patrick LandazuriKansas City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.